FDCDDQ
BCRX icon

Federation des caisses Desjardins du Quebec’s BioCryst Pharmaceuticals BCRX Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45.9K Hold
4,586
– – ﹤0.01% 1950
2026
Q1 		$43.7K Buy
4,586
+1,566
+52% +$12.2K ﹤0.01% 1898
2025
Q4 		$23.6K Buy
3,020
+626
+26% +$4.53K ﹤0.01% 2020
2025
Q3 		$18.2K Hold
2,394
– – ﹤0.01% 2069
2025
Q2 		$21.4K Buy
+2,394
New +$22.3K ﹤0.01% 1794
2021
Q3 		– Sell
-4,800
Closed -$75.9K – 2560
2021
Q2 		$75.9K Sell
4,800
-3,000
-38% -$40.8K ﹤0.01% 1482
2021
Q1 		$79.3K Sell
7,800
-6,200
-44% -$63.9K ﹤0.01% 1411
2020
Q4 		$104K Buy
+14,000
New +$72.2K ﹤0.01% 1267
2020
Q3 		– Sell
-6,200
Closed -$29.5K – 2168
2020
Q2 		$29.5K Buy
+6,200
New +$24.8K ﹤0.01% 1346
2018
Q2 		– Sell
-43,502
Closed -$207K – 2158
2018
Q1 		$207K Sell
43,502
-15,005
-26% -$77.1K ﹤0.01% 1007
2017
Q4 		$287K Hold
58,507
– – ﹤0.01% 953
2017
Q3 		$307K Buy
58,507
+24,619
+73% +$126K ﹤0.01% 907
2017
Q2 		$188K Buy
+33,888
New +$206K ﹤0.01% 1020

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's BCRX Position: Q2 2026 in Review

Federation des caisses Desjardins du Quebec held its BioCryst Pharmaceuticals (BCRX) position steady in Q2 2026 at 4,586 shares worth $45.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1950.

Federation des caisses Desjardins du Quebec first reported a position in BCRX in Q2 2017 and has held it in 13 quarters since. The position peaked at $307K in Q3 2017. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Federation des caisses Desjardins du Quebec held 4,586 shares of BioCryst Pharmaceuticals worth $45.9K as of Q2 2026.
  • Federation des caisses Desjardins du Quebec left its BioCryst Pharmaceuticals share count unchanged in Q2 2026.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Federation des caisses Desjardins du Quebec's portfolio in Q2 2026, its #1950 holding.
  • Federation des caisses Desjardins du Quebec first reported a position in BioCryst Pharmaceuticals in Q2 2017 and has held it in 13 quarters since.
  • Federation des caisses Desjardins du Quebec's BioCryst Pharmaceuticals position peaked at $307K in Q3 2017.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q2 2026, filed 14 Aug 2026.